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The superior efficacy of mannosylated neoglycoprotein-conjugated methotrcxatc,
compared with free drug, in eliminating the parasite burden in both the m-vitro
macrophage model and in-vivo mouse model of visceral leishmaniasis has been
demonstrated previously. In the present study it was found that: (I) methotrexate
conjugated to mannosyl human serum albumin (Man-HSA) was taken up rapidly by
the liver and spleen, whereas the free drug was taken up by the kidney; (ii) uptake of
the conjugate was ten-fold more efficient in liver macrophages (Kupffer cells) than in
hepatocytes; (iii) most of the drug conjugate reached the lysosomes of Kupfler cells;
and (IV) the active drug was released in the lysosomes of macrophages to act on
Leishmania parasites.
Introduction
The stability of glycoproteins and glycoconjugates in mammalian plasma is known to
be determined by the nature of exposed or terminal sugar residues associated with the
carbohydrate chains. Mannose-specific receptors are present exclusively on the surface
of differentiated macrophages, which are responsible for the internalization of
mannose-terminated glycoproteins infused i.v. (Gordon & Makena, 1989). Mannose
receptors are well-characterized in terms of their number/cell, their affinity for the
ligand, and turnover (Stahl et ai, 1980; Stahl & Gordon, 1982; Wileman, Boshans &
Stahl, 1985). Leishmania donovani, the causative agent of visceral leishmaniasis, is
known to be harboured and to multiply in the lysosomes of macrophages from spleen,
liver and bone-marrow in man (Chang & Fong, 1983). We have developed a macro-
phage-specific drug delivery system exploiting mannose receptors, with leishmaniasis as
the model macrophage disease. Methotrexate (MTX) was selected as the model drug,
with the neoglycoprotein, mannosyl human serum albumin (Man-HSA), as the carrier.
Methotrexate is an anti-tumour drug, but also has a profound antileishmanial effect
(Scott, Coombs & Sanderson, 1987; Chakraborty, Bhaduri & Das, 1990). The exclusive
expression of mannose receptors on the surface of macrophages, along with the
parasitic location of Leishmania amastigotes in macrophage lysosomes, formed the
basis of drug targeting. The leishmanicidal efficacy of the drug conjugate was found to
be almost 100-fold greater than that of the free drug on both the in-vitro macrophage
culture model and an in-vivo BALB/c mouse model of visceral leishmaniasis
(Chakraborty et al., 1990). The present study reports biodistribution studies designed
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to ascertain the physiological concentration, as well as the fate, of the drug in tissues
after conjugation with the carrier.
Materials and methods
Preparation of Man-HSA-(3H)-MTX conjugate
The neoglycoprotein, Man-HSA was prepared in a multi-step reaction by a modifica-
tion of the procedure described by Lemieux, Bundle & Baker (1975). In short,
8-methoxycarbonyloctylmannose was first synthesized by condensing acetobromoman-
nose with 8-ethoxycarbonyloctanol, followed by treatment with sodium methoxide in
dry methanol. The ester intermediate was coupled after hydrazinolysis with HSA by the
azide procedure at — 50°C. The final product was dialysed and lyophilized. The various
intermediates of mannose derivatives were characterized by spectroscopic and analy-
tical methods. The number of mannose residues was determined by the phenolsulphuric
acid method (Dubois et al., 1956), and was found to be 45 mol mannose/mol HSA.
(3H)-MTX was coupled to Man-HSA through l-ethyl-3(3-dimethylaminopropyl-carbo-
diimide hydrochloride (EDC) as described by Chakraborty et al. (1990). Almost
30 mols MTX were coupled/mol HSA.
Tissue distribution studies
BALB/c mice weighing c. 20-25 g were used throughout the experiment. Each mouse
received a single dose iv (through the tail vein) of 0-2 mL conjugate (0-34 mg protein)
containing 1 x 105 cpm (3H)-MTX. As a control, free (3H)-MTX and (3H)-MTX-HSA
were also injected. After time intervals of 5, 10 15, 30, 60 and 90 min, respectively,
groups of three mice were killed and the livers, kidneys, spleens and lungs were
removed. Each sample of tissue was washed with 0-9% saline and blotted with filter
paper. Concomitantly, 0-1 mL of blood was collected from the heart. Samples were
prepared for scintillation counting according to the method of Kimelberg (1976).
Tissue samples were solubilized, with 1 mL of Protosol (New England Nuclear,
Boston, MA, USA) for each 100 mg wet weight of tissue, and heated at 60°C for 3 h in
a water bath. After cooling, each sample was decolourized with 05 mL 30% H2O2.
Blood samples (0-1 mL) were solubilized in 1 mL Protosol for 1 h at room tempera-
ture, after which 05 mL isopropanol and 0-5 mL 30% H2O2 were added. All samples
treated with Protosol were neutralized with one-tenth the volume of 5 N HC1. All the
samples were dried at 45°C on filter paper discs (2-5 cm, GF/C; Whatman, Maidstone,
UK). Dried discs were immersed in 10 mL of scintillation fluid (Cocktail T:
Spectrochem, Bombay, India) and counted in a L55OO TD Liquid Scintillation Counter
(Beckman Instrument, Fullerton, CA, USA).
Sub-cellular fractionation of liver
After appropriate treatment, the mice were killed and their livers removed. The livers
were washed with 0-9% saline, and then blotted with filter paper. Each whole liver was
then homogenized in 0-32 M sucrose (4 mL/g tissue), and subsequently fractionated by
differential centrifugation into nuclear, mitochondrial-lysosomal, microsomal and
soluble fractions, as described by Gregoriadis & Sourkes (1967). Samples were
prepared with Protosol for scintillation counting as described earlier.
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Isolation of parenchymal and non-parenchymal cells
Liver cell suspensions were obtained by perfusion of liver in situ according to the
modified method of Berry & Friend (1969) and Munthe-Kaas & Seglen (1974), as
described by Murray (1987). Calcium-free Krebs-Henseleit buffer containing 0-025 M
HEPES was used as the perfusate. The concentration of collagenase was 0-03%.
Perfusion was discontinued after 25 min and the liver was cut into small pieces in
50 mL of oxygenated calcium-containing Krebs-Henseleit buffer. The mixture was
swirled gently for 2 min with a magnetic stirrer. The cell suspension was passed
through a 0-03 mm nylon mesh and centrifuged at 50 g for 2 min. Parenchymal cells
were sedimented and washed three times with the same buffer. The supernatant,
containing the nonparenchymal cells, was purified further by underlayering 23 mL of
the supernatant with 13 mL of metrizamide solution (16 g metrizamide, 0-24 g HEPES,
005 g KC1, 0018 g CaCl2- H2O, 5-5 mL 01 N NaOH, adjusted to 100 mL with water,
pH 7-6). Tubes were centrifuged for 45 min at 3000 g, after which the nonparenchymal
cells recovered from the metrizamide interphase were washed with calcium-containing
Krebs-Henseleit buffer, spun at 500 g for 3 min, resuspended in the same buffer, and
counted. In the competition experiments, yeast mannan (1 mg/mL) and Man-HSA
(2 mg/mL) were injected 5 min before Man-HSA-(3H)-MTX. Samples for radioactive
counting were prepared with Protosol as described earlier.
Sub-cellular fractionation of isolated liver cells
The cell suspensions were homogenized at 4°C in a Teflon Glass Homogeniser (Thomas
Scientific, Philadelphia, PA, USA), followed by sub-cellular fractionation as described
by Dasgupta & Bachhawat (1985). Radioactivity in each fraction was determined as
described earlier, and was expressed as a percentage of the total radioactivity present in
the homogenate before sub-cellular fractionation.
Degradation of drug conjugate by lysosomal enzymes
An extract of mouse liver lysosomes was prepared by methods similar to those of Das
6 Bishayee (1980). The drug conjugate was incubated in phosphate buffered saline
(pH 7-5) and citrate-phosphate buffer (005 M, pH 5-0) at 37°C in the presence of
lysosomal extract or trypsin as control. The proportion of Man-HSA-(3H)-MTX to
lysosomal extract or trypsin was taken as 1 : 10 or 1:1 respectively. Protein concentra-
tions were determined by the method of Lowry et al. (1951). 3H counts in the pellet and
supernatant were measured after precipitation with an equal volume of 20% TCA.
Results
Plasma clearance and tissue distribution pattern of methotrexate and its conjugates
Figure 1 compares the 3H counts in plasma after administration iv of comparable
amounts of free MTX, Man-HSA-(3H)-MTX, and HSA-(3H)-MTX. Plasma clearance
was much faster for both free MTX and Man-HSA-MTX compared with HSA-MTX.
The Ti was 4 min for free MTX, and 10 min for Man-HSA-MTX, whereas for
HSA-MTX it was 25 min. This rapid clearance of Man-HSA-MTX resulted perhaps
from rapid uptake by the liver and spleen, as evidenced by tissue distribution studies
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Figure 1. Blood levels of 3H in mice following administration IV of. (3H)-MTX (O); Man-HSA-(3H)-MTX
( • ) , and HSA-(3H)-MTX (A)- Mean ±standard deviation of three mice/group
(Table I). After 15 min, 52% of the administered Man-HSA-MTX was recovered
(relative radioactivity/100 mg tissue) in the liver, and 13% in the spleen. In contrast,
the rapid clearance of free MTX resulted probably from its substantial accumulation in
the kidney (36%). The uptake rates of the various forms of (3H)-MTX by the liver are
shown in Figure 2. For all the drug forms, the maximum uptake of (3H)-MTX was
15 min after administration. However, in each case, there was a subsequent gradual
decrease in the amount of (3H)-MTX in the liver. The tissue levels of (3H)-MTX reflect
the difference between uptake and possible clearance and loss. The possible role (if any)
of the protein carrier on the clearance of drug from the liver has not been investigated.
Sub-cellular distribution of the various forms of (3H)-MTX in the liver
At the time point of highest uptake of MTX-neoglycoprotein conjugate, sub-cellular
fractionation of liver by differential centrifugation revealed that most of the manno-
sylated drug conjugate had reached the lysosome-rich fraction; almost 55% of the total
count, compared with 20% and 41% for free MTX and HSA-MTX, respectively
Table I. Tissue distribution of various forms of (3H)-MTX, measured 15 min after administration
iv. Values shown are means of four independent observations
% Injected dose/organ
Organ (3H)-MTX HSA-<3H)-MTX Man-HSA-(3H)-MTX
Liver
Spleen
Kidney
Lung
101 + 1-8
6-2+1-1
36-4 + 4-2
0-5 + 01
18-2±2-5
9-3 ±1-6
81 ±06
0-4 + 0-1
514 + 7-8
13-3 + 2-7
4-1+0-5
0-4 + 0-1
 by guest on February 9, 2011
jac.oxfordjournals.org
D
ow
nloaded from
 
Biodistribution of methotrexate 155
100
S? 4 0 -
Figure 2. Uptake rates of various forms of (3H)-MTX by mouse liver ('H)-MTX (O).
Man-HSA-('H)-MTX ( • ) . and HSA-(3H)-MTX (A)- Mean±standard deviation of three mice/group.
(Table II). Uptake of HSA-MTX by the lysosome-rich fraction was greater than
uptake of free MTX, probably because of the high concentration of phagocytic cells in
this tissue. The further enhancement observed with mannose substitution indicated the
special role of mannose receptors in the process of receptor-mediated endocytosis. The
greater accumulation of free MTX in the soluble supernatant fraction indicated its
presence in extracellular fluid and/or passive transport to cytosol.
Table II. Sub-cellular distribution of (3H)-MTX in the liver, measured 15 min after
administration iv. Values shown are means of four independent observations
Fraction
Original
homogenate
Cell debris-
nuclear
Mitochondrial
lysosome
Microsome
Soluble
supernatant
fraction
(3H)-MTX
cpmx lfr3
81 ± 11
2-2+ 0-5
1-6 ±0-2
0-6 + 0-1
3-2 + 0-5
% of
total
100
27-2
19 8
7-4
39-5
HSA-(3H)-MTX
cpm x 10~3
17-5 + 2-1
4-5 + 0-7
71 + 11
2-1+0-4
31 ±0-4
% of
total
100
25-7
40-6
120
17-7
Man-HSA-(
cpm x 10"3
49-8 ±4-2
103+1-5
27-2 + 3-3
3-6±0-7
5-8 ±0-8
3H)-MTX
% of
total
100
20-7
54-6
7-2
11-6
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Table HI. Uptake of various forms of (3H)-MTX by mouse liver cells. Values shown are means of
four independent observations made 15 min after administration
Experiment
(3H)-MTX
HSA-(3H)-MTX
Man-HSA-(3H)-MTX
Man-HSA-(3H)-MTX + Man-HSA
(2 mg/mL)
Man-HSA-(3H)-MTX + Mannan
(1 mg/mL)
Radioactivity
infused
(cpmx 10"5)
50
5-0
50
5-0
50
Radioactivity
(cpm/mg cell
Hepatocytes
327 ±33
475 ±57
276 ±32
524 ± 71
465 ±56
protein ±S.D.)
Non-parenchymal
214±38
783±81
2562 ±363
887 ±102
1120±118
Uptake of methotrexate and its conjugates by mouse liver cells
Parenchymal and non-parenchymal mouse liver cells were separated after i.v. adminis-
tration of (3H)-MTX, or its conjugates, and the counts of (3H)-MTX were measured. It
was found that non-parenchymal cells were ten-fold more efficient than hepatocytes in
the assimilation of Man-HSA-(3H)-MTX, as evidenced by the comparison of radio-
activity/mg cell protein (Table III). The uptake was also greater for HSA-(3H)-MTX,
and almost double in non-parenchymal cells compared with hepatocytes. This probably
resulted from non-specific engulfment of HSA-(3H)-MTX by liver macrophages. In
contrast, the distribution pattern of free (3H)-MTX indicated non-specific passive
transport to various liver cells; uptake was higher in hepatocytes than in non-
parenchymal cells, possibly because of the variation in their size, shape and disposition.
Enhanced uptake of Man-HSA-MTX was found to be inhibited competitively by
mannan and Man-HSA. This indicated a possible involvement of hepatic mannose
receptors in the recognition of Man-HSA-MTX by the Kupffer cells which, in turn,
may be responsible for enhanced uptake of this drug form by the liver.
Sub-cellular distribution in isolated liver cell types
In general, the content of neoglycoprotein-conjugated drug was higher in lysosome-rich
fractions of both hepatocytes and non-parenchymal cells than in other fractions such as
Table IV. Relative sub-cellular distribution of the various forms of MTX in mouse liver cells.*
Values shown are means of four independent observations made 15 min after administration
Experiment
(3H)-MTX
HSA-(3H)-MTX
Man-HSA-(3H)-MTX
Parenchymal cells
Mitochondnal/
lysosome
fraction
23-6 ±3-6
32-8 ±4-4
43-5 + 6-2
Plasma and
nuclear
membrane
fraction
58-6 + 4-2
39-4 ±5-2
35-4 ±4-3
Non-parenchymal cells
Mitochondrial/
lysosome
fraction
20-3 + 3-4
30-7 ±5-4
53-5 ±51
Plasma and
nuclear
membrane
fraction
62-2 + 5-3
42-5 + 50
24-7 ±3-1
'Percentage of total count in isolated cell fractions
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Table V. Degradation of Man-HSA-MTX in the presence of lysosomal enzymes. Values shown
are means of four independent observations made 15 min after administration
Experiment
No enzyme
Trypsin
Lysosomal extract
pH
TCA-soluble
11+0-1
52-6 + 4-2
16-4+ 0-9
(3H)-MTX count
7-5
TCA-insoluble
98-6 ±0-4
44-7 + 3-8
82-3 ±2-8
(% of total)
PH
TCA-soluble
0-6±Ol
31-7+1-9
58-8 ±3-2
5-0
TCA-insoluble
991+0-5
66-2 + 3-9
38-6 + 2-6
the plasma membrane and nuclear membrane fraction (Table IV). Again, this indicated
possible entry into cells through an endocytotic process. In contrast, most free MTX
was associated with the plasma membrane and nuclear membrane fraction.
Degradation of Man-HSA-MTX by lysosomal enzymes
To ascertain whether the active drug was released from the neoglycoprotein conjugate,
Man-HSA-MTX was incubated in the presence of lysosomal extract from mouse liver
at pH 50 and 7-5 (Table V). Trypsin was used as a control. Trypsin was able to
catalyse degradation of the conjugate at both pH values, although the rate of
degradation was much faster at pH 7-5 (52-6% TCA soluble radioactivity, compared
with 31-7% at pH 50). Almost 60% of the bound drug was released from the
neoglycoprotein carrier when incubated with lysosomal extract at pH 5-0. Only 16% of
the drug was released when incubated at pH 7-5. This indicated that much of the
delivered drug is freed from its carrier in the phagolysosomes of macrophages.
Discussion
The challenge in therapeutics is to develop drugs that can be delivered selectively to the
target site. Since imparting target selectivity on to the drug itself is a difficult and
uncertain proposition, much attention is being devoted to the development of drug
delivery systems that can carry otherwise non-selective drugs to the appropriate
infected site. Of all the drug carrier systems presently available, liposomes seem to be
the most versatile (Ostro, 1987; Leserman et al., 1990). However, one of the major
limitations of liposomal delivery system is their instability and limited shelf-life.
Chemical conjugation of drugs to carriers, such as antibodies raised against target cells
or their membranes, have been investigated extensively (Pastan, Willingham &
FitzGerald, 1986; Worrell et al., 1986). Such conjugated drugs, although highly
successful in killing target cells in vitro, have limited potency in vivo. As an alternative,
neoglycoproteins have been investigated as a potential drug carrier system.
Methotrexate conjugated to mannosylated bovine serum albumin (Man-BSA) was
found to be highly-efficient in suppressing the parasite burden in both the in-vitro
macrophage model and in-vivo mouse model of visceral leishmaniasis (Chakraborty et
al., 1990). This targeting efficiency is not surprising considering the fact that some
lysosomal enzymes and serum glycoproteins are cleared rapidly and specifically from
the circulation by a receptor-mediated endocytotic process (Stahl et al., 1976), and
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receptors are present on matured macrophages which are specific for a-mannose
terminated glycoproteins.
In the present study, it was found that there was a striking pharmacokinetic
difference between the drug and its conjugate. Methotrexate conjugated to HSA with a
mannose residue is cleared rapidly from blood, and displays all the characteristics of
receptor-mediated endocytosis. The prompt disappearance of Man-HSA-MTX from
the circulation, increased uptake by the liver and spleen, the relatively greater assimila-
tion by Kupffer cells, and the inhibition of uptake by both Man-HSA and mannan,
suggest that the drug conjugate is taken-up specifically by liver Kupffer cells as a direct
consequence of the specific interaction of exposed mannosyl residues with the mannose-
binding protein described by Stahl (1990). The drug conjugate reaches the liver
macrophages in large quantities, particularly in the lysosomes. The drug is then cleaved
from the conjugate and is released in the lysosome, i.e. the precise location where
Leishmania amastigotes multiply. The entire pharmacokinetic and biodistribution
studies argue clearly in favour of constructing a drug delivery system based on a
neoglycoprotein that can carry and release an active drug at the appropriate diseased
site through a receptor-mediated endocytotic process.
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